

As indicated in the preamble of independent Claim 1 of Group I, the claims of Group I, Claims 1-7, 11, 12, 17-19, 21 and 22, recite "a mucoadhesive composition for solubilizing of *insoluble drugs*" comprising a monoglyceride and an oil (emphasis added). Thus, an insoluble drug is always involved in using the mucoadhesive composition according to the claims of Group I. The claims of Group III particularly recite the insoluble drug. Given such, there is a close relationship between the inventions listed as Groups I and III, based on this relationship, the Applicants respectfully request that at least the claims of Group I be examined along with elected Group III claims.

The Applicants expressly reserve the right under 35 USC §121 to file a divisional application directed to the non-elected subject matter or any subject matter disclosed in this application during the pendency of this application.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number HANO-004.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: January 14, 2008

By: Shinae Kim-Helms  
Shinae Kim-Helms  
Registration No. 57,552

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231